uz
Feedback
Pediatrics

Pediatrics

Kanalga Telegram’da o‘tish

libros y aplicaciones para pediatria

Ko'proq ko'rsatish

📈 Telegram kanali Pediatrics analitikasi

Pediatrics (@librospediatria) Ingliz til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 19 268 obunachidan iborat bo'lib, Tibbiyot toifasida 1 206-o'rinni va Birlashgan Qirollik mintaqasida 569-o'rinni egallagan.

📊 Auditoriya ko‘rsatkichlari va dinamika

невідомо sanasidan buyon loyiha tez o‘sib, 19 268 obunachiga ega bo‘ldi.

29 Iyun, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 484 ga, so‘nggi 24 soatda esa 6 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya o‘rtacha 27.53% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining N/A% ini tashkil etuvchi reaksiyalarni to‘playdi.
  • Post qamrovi: Har bir post o‘rtacha 5 297 marta ko‘riladi; birinchi sutkada odatda 0 ta ko‘rish yig‘iladi.
  • Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 19 ta reaksiya keladi.
  • Tematik yo‘nalishlar: Kontent act, exacerbation, pediatric, guideline, 0–27 kabi asosiy mavzularga jamlangan.

📝 Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
libros y aplicaciones para pediatria

Yuqori yangilanish chastotasi (oxirgi ma’lumot 30 Iyun, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.

19 268
Obunachilar
+624 soatlar
+1117 kunlar
+48430 kunlar
Postlar arxiv
+1
Pediatrics In Review - June 2026.pdf1.61 MB

GINA 2026 Ingles
+3
GINA 2026 Ingles

GINA 2026 Españo
+3
GINA 2026 Españo

The Harrit lane 24th ed. 2027.pdf14.50 MB

PALS 2025.pdf47.61 MB

chatburn_2026_how_to_interpret_ventilator_waveforms_using_the_taxonomy.pdf

Pals Español_2025.pdf6.52 MB

Guidelines_for_the_Management_of_Severe_Traumatic.97250__2_.pdf1.45 KB

From now on, BiliApp is recognised as a digital health innovation application, as it is included in the Digital Solutions Cat
From now on, BiliApp is recognised as a digital health innovation application, as it is included in the Digital Solutions Catalogue of the Royal College of Paediatrics and Child Health, an academic and scientific reference institution in paediatrics in England and the United Kingdom, within its Digital Health Hub 🌐 RCPCH Digital Health Hub: https://hub.rcpch.digital/ 📲 Download BiliApp: ✅️App Store (iOS-Iphone): ✅️Google Play (Android):

Síndrome de distrés respiratorio agudo en el paciente__crítico pediátrico.pdf

2025 Textbook of Neonatal Resuscitation 9ed - AAP (1).pdf

Pediatric_Basic_Life_Support_2025_American_Heart_Association_and.pdf

Neonatal_Resuscitation_2025_American_Heart_Association_and_American.pdf

Pediatric_Advanced_Life_Support_2025_American_Heart_Association.pdf

Highlights_of_the_2025_American_Heart_Association_Guidelines_for.pdf

2025 algorithms - AHA.pdf

🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in 🇬🇧 Engl
🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in 🇬🇧 English, 🇪🇸Español, 🇧🇷 Português,🇫🇷 Français, 🇩🇪Deutsch, 🇮🇹Italiano, and 🇷🇺Русский. 📲 Download now: 🔹 App Store 🔹 Google Play

🩺 BiliApp – Neonatal Hyperbilirubinemia Management Based on AAP and NICE 2025 clinical guidelines. 🌍 Available in English, Español, Português, Français, Deutsch, Italiano, and Русский. 📲 Download now: 🔹 App Store 🔹 Google Play

🚀 Asthma Control Test AppFree tool to assess & monitor asthma control in adults and children 📱 Download here: 🍏 iPhone: Link 🤖 Android: Link 🌍 Available in 6 languages: 🇬🇧 English, 🇪🇸 Spanish, 🇫🇷 French, 🇮🇹 Italian, 🇧🇷 Portuguese, 🇩🇪 German

🌬️ Key Facts about the Asthma Control Test (ACT/C-ACT) — for Pediatricians 1️⃣ Population & instruments 👩‍🦰👦 ACT: ≥12 y (5 items, 4-week recall). C-ACT: 4–11 y (7 items; child + caregiver). [link](https://www.jacionline.org/article/S0091-6749%2807%2900167-4/fulltext) 2️⃣ Scores & cut-offs used in practice 📊 ACT: 5–25; >19 = well controlled, ≤19 = not well controlled. C-ACT: 0–27; ≤19 = not well controlled. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://pubmed.ncbi.nlm.nih.gov/17353040/) 3️⃣ Minimal Clinically Important Difference (MCID) 🔄 For ACT, a ±3-point change reflects a clinically meaningful improvement/worsening and predicts differential risk in outcomes. [link](https://www.jacionline.org/article/S0091-6749%2809%2901245-7/fulltext) 4️⃣ Validity & reliability (psychometrics + physiology) 📈 ACT shows internal consistency \~0.84–0.85 and test–retest \~0.77; correlates with specialist control ratings and FEV₁. [link](https://pubmed.ncbi.nlm.nih.gov/16522452/) | [link](https://www.thoracic.org/members/assemblies/assemblies/srn/questionaires/act.php) 5️⃣ Prognostic value (risk of exacerbations) 🔮 Lower ACT scores associate with higher SABA use/exacerbation risk; maintaining ACT ≥ 20 reduces exacerbation risk. [link](https://www.sciencedirect.com/science/article/pii/S0954611119300460) | [link](https://pubmed.ncbi.nlm.nih.gov/19767070/) | [link](https://pmc.ncbi.nlm.nih.gov/articles/PMC7118934/) 6️⃣ How to apply (guideline context) 🩺 Use ACT/C-ACT with symptom history, prior exacerbations, and objective measures (e.g., spirometry) to guide step-wise therapy per GINA 2024. [link](https://ginasthma.org/wp-content/uploads/2024/12/GINA-Summary-Guide-2024-WEB-WMS.pdf)